Cyclic lipodepsipeptides: A new class of antibacterial agents in the battle against resistant bacteria

Future Medicinal Chemistry

Volumn 5, Issue 11, 2013, Pages 1311-1330

  Bionda, Nina ^a   Pitteloud, Jean Philippe ^a   Cudic, Predrag ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 21978C; ANTIINFECTIVE AGENT; CYCLIC LIPODEPSIPEPTIDE; DAPTOMYCIN; ENRAMYCIN; FUSARICIDIN; RAMOPLANIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COMMUNITY ACQUIRED PNEUMONIA; DNA SYNTHESIS; DRUG CLASSIFICATION; DRUG CONFORMATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG SCREENING; ENTEROCOCCUS FAECALIS; GENETIC ENGINEERING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MEMBRANE DEPOLARIZATION; NUCLEAR MAGNETIC RESONANCE; OPEN READING FRAME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; POTASSIUM CELL LEVEL; POTASSIUM DEPLETION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA SYNTHESIS; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS AUREUS; STEADY STATE; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; TOXICITY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; DAPTOMYCIN; DEPSIPEPTIDES; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84893356438     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.86     Document Type: Review

References (137)

1. Gold HS, Moellering RC. Antimicrobial-drug resistance. N. Engl. J. Med. 335(19), 1445-1453 (1996).
2. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol. 9, 438-444 (2001).
3. Fluit AC, Schmitz FJ, Verhoef J. Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens. Int. J. Antimicrob. Agents 18(2), 147-160 (2001).
4. Spellberg B, Guidos R, Gilbert D, et al.: The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164. (2008).
5. Rice LB. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. 71, 133-139. (2006).
6. Boucher HW, Talbot GH, Bradley JS, et al.: Bad bugs, no drugs: No ESKAPE! an update from the Infectious Diseases Society of America. Clin. Infec. Dis. 48(1), 1-12. (2009).
7. Boneca IG, Chiosis G. Vancomycin resistance: Occurrence, mechanisms and strategies to combat it. Expert Opin. Ther. Targets 7(3), 311-328 (2003).
8. Bionda N, Cudic P. Cyclic lipodepsipeptides in novel antimicrobial drug discovery. Croat. Chem. Acta 84(2), 315-329 (2011).
9. Giuliani A, Pirri GP, Nicoletto SF. Antimicrobial peptides: An overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2(1), 1-33 (2007).
10. Roongsawang N, Washio K, Morikawa M. Diversity of nonribosomal peptide synthetases involved in the biosynthesis of lipopeptide biosurfactants. Int. J. Molec. Sci. 12(1), 141-172 (2010).
11. Marahiel MA. Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis. J. Pept. Sci. 15(12), 799-807 (2009).
12. Sieber SA, Marahiel MA. Learning from nature's drug factories: Nonribosomal synthesis of macrocyclic peptides. J. Bacteriol. 185(24), 7036-7043 (2003).
13. Grünewald J, Marahiel MA. Chemoenzymatic and template-directed synthesis of bioactive macrocyclic peptides. Microbiol. Mol. Biol. Rev. 70(1), 121-146 (2006).
14. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin. Investig. Drugs 12(2), 117-137 (2003).
15. Kern WV. Daptomycin: First in a new class of antibiotics for complicated skin and soft-Tissue infections. Int. J. Clin. Pract. 60(3), 370-378 (2006).
16. Vilhena C, Bettencourt A. Daptomycin: A review of properties, clinical use, drug delivery and resistance. Mini Rev. Med. Chem. 12(3), 202-209 (2012).
17. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infec. Dis. 38(12), 1673-1681 (2004).
18. Fowler VG, Boucher HW, Corey GR, et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355(7), 653-665 (2006).
19. Sivakumar B, Vijaysegaran P, Chaudhuri A, Crawford S, Ottley M. Daptomycin resistance in prosthetic joint infections. Orthopedics 35(4), e603-e606 (2012).
20. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin. Proc. 80(9), 1215-1216 (2005).
21. Mishra NN, Bayer AS, Tran TT, et al.: Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS ONE 7(8), e43958 (2012).
22. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42(11), 1652-1653 (2006).
23. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50(3), 1079-1082 (2006).
24. Cafiso V, Bertuccio T, Spina D, et al.: Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS ONE 7(1), e29573 (2012).
25. Farver DK, Hedge DD, Lee SC. Ramoplanin: A lipoglycodepsipeptide antibiotic. Ann. Pharmacother. 39(5), 863-868 (2005).
26. Barrett JF. Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs 6(8), 781-790 (2005).
27. Eckert R Road to clinical efficacy: Challenges and novel strategies for antimicrobial peptide development Future Microbiol. 6(6), 635-651 (2011).
28. Shah D, Dang MD, Hasbun R, et al.: Clostridium difficile infection: Update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev. Anti Infect. Ther. 8(5), 555-564 (2010).
29. Kurusu K, Ohba K. New peptide antibiotics LI-F03, F04, F05, F07, and F08, produced by Bacillus polymyxa. I. Isolation and characterization J. Antibiot. 40, 1506-1514 (1987).
30. Kajimura Y, Kaneda M. Fusaricidin A, a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity J. Antibiot. 49, 129-135 (1996).
31. Kajimura Y, Kaneda M. Fusaricidins B, C and D, new depsipeptide antibiotics produced by Bacillus polymyxa KT-8: Isolation, structure elucidation and biological activity J. Antibiot. 50, 220-228 (1997).
32. Kuroda J, Fukai T, Konishi M, Uno J, Kurusu K, Nomura T. LI-F antibiotics, a family of antifungal cyclic depsipeptides produced by Bacillus polymyxa l-1129. Heterocycles 53, 1533-1549 (2000).
33. Bionda N, Stawikowski M, Stawikowska R, et al.: Effects of cyclic lipodepsipeptide structural modulation on stability, antibacterial activity and human cell toxicity. Chem. Med. Chem. 7(5), 871-882 (2012).
34. Debono M, Barnhart M, Carrell CB, Hoffman JA, Hamill RL. A21978C, a complex of new acidic peptide antibiotics: Factor definition and preliminary chemical characterization. Presented at: Program and Abstracts of 20th Intersci. Conference on Antimicrobial Agents and Chemtherapy. New Orleans, LA, USA, 22-24 September 1980.
35. Counter FT, Ensminger PW, Howard LC. A21978C, a complex of new acidic peptide antibiotics: Biological activity and toxicity. Presented at: Program and Abstracts of 20th Intersci. Conference on Antimicrobial Agents and Chemtherapy. New Orleans, LA, USA, 22-24 September 1980.
36. Miao V, Coeffet-LeGal M-F, Brian P, et al.: Daptomycin biosynthesis in Streptomyces roseosporus: Cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151(5), 1507-1523 (2005).
37. Debono M, Barnhart M, Carrell CB, et al.: A21978C, a complex of new acidic peptide antibiotics: Isolation, chemistry and mass spectral structure elucidation. J. Antibiot. 40, 761-777 (1987).
38. Eliopoulos GM, Thauvin C, Gerson B, Moellering Jr. RC. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 27(3), 357-362 (1985).
39. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45(6), 1919-1922 (2001).
40. Lakey JH, Lea EJA. The role of acyl chain character and other determinants on the bilayer activity of A21978C an acidic lipopeptide antibiotic. BBA Biomembranes 859(2), 219-226 (1986).
41. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(8), 2538-2544 (2003).
42. Lakey JH, Maget-Dana R, Ptak M. The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions. BBA Biomembranes 985(1), 60-66 (1989).
43. Jung D, Rozek A, Okon M, Hancock REW. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11(7), 949-957 (2004).
44. Allen N, Alborn W, Hobbs J, Percifield H. LY146032 inhibits the biosynthesis of cell wall peptidoglycan in gram-positive bacteria. Presented at: Program Abstract of the 24th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 8-10 October 1984.
45. Debono M, Abbot BJ, Molloy MR, et al.: Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: The synthesis and evaluation of daptomycin (LY146032). J. Antibiot. 41, 1093-1105 (1988).
46. Huber FM, Pieper RL, Tietz AJ. The formation of daptomycin by supplying decanoic acid to Streptomyces roseosporus cultures producing the antibiotic complex A21978C. J. Biotechnol. 7(4), 283-292 (1988).
47. Baltz RH. Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin. Curr. Top. Med. Chem. 8(8), 618-638 (2008).
48. Baltz RH, Miao V, Wrigley SK. Natural products to drugs: Daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 22(6), 717-741 (2005).
49. Grünewald J, Sieber SA, Marahiel MA. Chemo-And regioselective peptide cyclization triggered by the N-Terminal fatty acid chain length: The recombinant cyclase of the calcium-dependent antibiotic from Streptomyces coelicolor. Biochemistry 43(10), 2915-2925 (2004).
50. Kopp F, Grünewald J, Mahlert C, Marahiel MA. Chemoenzymatic design of acidic lipopeptide hybrids: New insights into the structure activity relationship of daptomycin and A54145. Biochemistry 45(35), 10474-10481 (2006).
51. Nguyen KT, Ritz D, Gu J-Q, et al.: Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl Acad. Sci. USA 103(46), 17462-17467 (2006).
52. Hill J, Siedlecki J, Parr I, et al.: Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin. Bioorg. Med. Chem. Lett. 13(23), 4187-4191 (2003).
53. Allen NE, Hobbs JN, Alborn WE, Jr. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. 31(7), 1093-1099 (1987).
54. Hobbs JK, Miller K, O'Neill AJ, Chopra I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemoth. 62(5), 1003-1008 (2008).
55. Tally FP, Zeckel M, Wasilewski MM, et al.: Daptomycin: A novel agent for Gram-positive infections. Expert Opin. Investig. Drugs 8(8), 1223-1238 (1999).
56. Oleson FB, Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. 44(11), 2948-2953 (2000).
57. LaPlante KL, Rybak MJ. Daptomycin-A novel antibiotic against Gram-positive pathogens. Expert Opin. Pharmacother. 5(11), 2321-2331 (2004).
58. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin. Invest. Drugs 13(9), 1159-1169 (2004).
59. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34(10), 1925-1931 (1990).
60. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35(12), 2505-2508 (1991).
61. Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect. 55(3), 205-213 (2007).
62. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem. Biol. Interact. 150(2), 137-147 (2004).
63. Silverman JA, Mortin LI, Vanpraagh ADG, Tongcliuan L, Alder J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J. Infect. Dis. 191(12), 2149-2152 (2005).
64. Pertel PE, Bernardo P, Fogarty C, et al.: Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-Acquired pneumonia. Clin. Infec. Dis. 46(8), 1142-1151 (2008).
65. Nguyen KT, He X, Alexander DC, et al.: Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. Antimicrob. Agents Chemother. 54(4), 1404-1413 (2010).
66. Baltz RH. Combinatorial biosynthesis of cyclic lipopeptide antibiotics: A model for synthetic biology to accelerate the evolution of secondary metabolite biosynthetic pathways. ACS Synth. Biol. (2012).
67. Counter FT, Allen NE, Fukuda DS, et al.: A54145 a new lipopeptide antibiotic complex: Microbiological evaluation. J. Antibiot. 43(6), 616-622 (1990).
68. Boeck LD, Wetzel RW. A54145, a new lipopeptide antibiotic complex: Factor control through precursor directed biosynthesis. J. Antibiot. 43(6), 607-615 (1990).
69. Fukuda DS, Du Bus RH, Baker PJ, Berry DM, Mynderse JS. A54145, a new lipopeptide antibiotic complex: Isolation and characterization. J. Antibiot. 43(6), 594-600 (1990).
70. Alexander DC, Rock J, Gu J-Q, et al.: Production of novel lipopeptide antibiotics related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment od IptJ, IptK and IptL gene functions. J. Antibiot. 64, 79-87 (2011).
71. Alexander DC, Rock J, He X, Brian P, Miao V, Baltz RH. Development of a genetic system for combinatorial biosynthesis of lipopeptides in Streptomyces fradiae and heterologous expression of the A54145 biosynthesis gene cluster. Appl. Environ. Microbiol. 76(20), 6877-6887 (2010).
72. Gu J-Q, Alexander DC, Rock J, Brian P, Chu M, Baltz RH. Structural characterization of a lipopeptide antibiotic A54145E(Asn3Asp9) produced by a genetically engineered strain of Streptomyces fradiae. J. Antibiot. 64, 111-116 (2011).
73. Arias CA, Panesso D, McGrath DM, et al.: Genetic basis for in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365(10), 892-900 (2011).
74. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: Evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54(8), 3079-3085 (2010).
75. Yang SJ, Xiong YQ, Dunman PM, et al.: Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53(6), 2636-2637 (2009).
76. Mishra NN, Yang SJ, Sawa A, et al.: Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53(6), 2312-2318 (2009).
77. Bayer AS, Prasad R, Chandra J, et al.: In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect. Immun. 68(6), 3548-3553 (2000).
78. Jones T, Yeaman MR, Sakoulas G, et al.: Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52(1), 269-278 (2008).
79. Mishra NN, Liu GY, Yeaman MR, et al.: Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55(2), 526-531 (2011).
80. Camargo IL, Neoh HM, Cui L, Hiramatsu K. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52(12), 4289-4299 (2008).
81. Mishra NN, McKinnell J, Yeaman MR, et al.: In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55(9), 4012-4018 (2011).
82. Cui L, Ma X, Sato K, et al.: Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41(1), 5-14 (2003).
83. Mehta S, Cuirolo AX, Plata KB, et al.: VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56(1), 92-102 (2012).
84. Peleg AY, Miyakis S, Ward DV, et al.: Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS ONE 7(1), e28316 (2012).
85. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55(7), 3345-3356 (2011).
86. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50(6), 2137-2145 (2006).
87. Cui L, Isii T, Fukuda M, et al.: An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 54(12), 5222-5233 (2010).
88. Julian K, Kosowska-Shick K, Whitener C, et al.: Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51(9), 3445-3448 (2007).
89. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Jr., Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51(6), 2223-2225 (2007).
90. Ernst CM, Staubitz P, Mishra NN, et al.: The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5(11), e1000660 (2009).
91. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J. Med. Microbiol. 57(8), 1036-1038 (2008).
92. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physicochemical characteristics J. Antibiot. 37, 309-317 (1984).
93. Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. III. Structure elucidation. J. Antibiot. 42, 254-266 (1989).
94. Kurz M, Guba W. 3D structure of ramoplanin: A potent inhibitor of bacterial cell wall synthesis. Biochemistry 35(38), 12570-12575 (1996).
95. Shin D, Rew Y, Boger DL. Total synthesis and structure of the ramoplanin A1 and A3 aglycons: Two minor components of the ramoplanin complex. Proc. Natl Acad. Sci. USA 101(33), 11977-11979 (2004).
96. Skelton NJ, Harding MM, Mortishire-Smith RJ, et al.: Structure elucidation and solution conformation of the glycopeptide antibiotic ramoplanose (UK-71,903): A cyclic depsipeptide containing an antiparallel b-sheet and a b-bulge. J. Am. Chem. Soc. 113, 7522-7530 (1991).
97. Higashide E, Hatano K, Shibata M, Nakazawa K. Enduracidin, a new antibiotic. I. Streptomyces fungicidicus No. B 5477, an enduracidin producing organism. J. Antibiot. 21, 126-137 (1968).
98. Asai M, Muroi M, Sugita N, Kawashima H, Mizuno K, Miyake A. Enduracidin, a new antibiotic. II. Isolation and characterization J. Antibiot. 21, 138-146 (1968).
99. Cudic P, Behenna DC, Kranz JK, et al.: Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin. Chem. Biol. 9(8), 897-906 (2002).
100. Lo M-C, Helm JS, Sarngadharan G, Pelczer I, Walker S. A new structure for the substrate-binding antibiotic ramoplanin. J. Am. Chem. Soc. 123(35), 8640-8641 (2001).
101. Hamburger JB, Hoertz AJ, Lee A, Senturia RJ, McCafferty DG, Loll PJ. A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential lipid II docking interface. Proc. Natl Acad. Sci. USA 106(33), 13759-13764 (2009).
102. Castiglione F, Marazzi A, Meli M, Colombo G. Structure elucidation and 3D solution conformation of the antibiotic enduracidin determined by NMR spectroscopy and molecular dynamics. Magn. Reson. Chem. 43(8), 603-610 (2005).
103. Pallanza R, Berti M, Scotti R, Randisi E, Arioli V. A-16686, a new antibiotic from Actinoplanes. II. Biological properties J. Antibiot. 37, 318-324 (1984).
104. Neu HC, Neu NM. In vitro activity of A-16686, a new glycopeptide. Chemotherapy 32(5), 453-457 (1986).
105. Johnson CC, Taylor S, Pitsakis P, May P, Levison ME. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob. Agents Chemother. 36(10), 2342-2345 (1992).
106. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering Jr. RC. In vitro activity of ramoplanin against vancomycin-resistant Gram-positive organisms Antimicrob. Agents Chemother. 37, 1364-1366 (1993).
107. Jones RN, Barry AL. In vitro evaluation of ramoplanin (A16686 or MDL62198): A new depsipeptide complex for potential topical use. Diagn. Micr. Infect. Dis. 12, 279-282 (1989).
108. Francis J, Webster H, Newsom SWB. In vitro activity of ramoplanin on Staphylococci. Drugs Exp. Clin. Res. 16, 457-460 (1990).
109. Maple PAC, Hamilton-Miller JMT, Brumfitt W. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus. J. Antimicrob. Chemother. 23(4), 517-525 (1989).
110. Gastaldo L, Ciabatti R, Assi F, et al.: Isolation, structure determination and biological activity of A-16686 factors Á 1, Á 2 and Á 3 glycolipodepsipeptide antibiotics. J. Ind. Microbiol. Biot. 11(1), 13-18 (1992).
111. Goto S, Kuwahara S, Okubo N, Zenyoji H. In vitro and in vivo evaluation of enduracidin, a new peptide antibiotic substance. J. Antibiot. 21(2), 119-125 (1968).
112. Jiang W, Wanner J, Lee RJ, Bounaud P-Y, Boger DL. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc. 124(19), 5288-5290 (2002).
113. Maplestone RA, Cox JPL, Williams DH. Retention of native-like structure in an acyclic counterpart of a b-sheet antibiotic. FEBS Lett. 326(1-3), 95-100 (1993).
114. Jiang W, Wanner J, Lee RJ, Bounaud P-Y, Boger DL. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc. 125(7), 1877-1887 (2003).
115. Rew Y, Shin D, Hwang I, Boger DL. Total synthesis and examination of three key analogues of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. J. Am. Chem. Soc. 126(4), 1041-1043 (2004).
116. Chen L, Yuan Y, Helm JS, et al.: Dissecting ramoplanin: Mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J. Am. Chem. Soc. 126(24), 7462-7463 (2004).
117. Nam J, Shin D, Rew Y, Boger DL. Alanine scan of [l-Dap2]ramoplanin A2 aglycon: Assessment of the importance of each residue. J. Am. Chem. Soc. 129(28), 8747-8755 (2007).
118. Ciabatti R, Maffioli SI, Panzone G, et al.: Synthesis and preliminary biological characterization of new semisynthetic derivatives of ramoplanin. J. Med. Chem. 50(13), 3077-3085 (2007).
119. Gandolfi R, Marinelli F, Ragg E, Romano D, Molinari F. Chemoenzymatic deacylation of ramoplanin. Bioorg. Med. Chem. Lett. 22(16), 5283-5287 (2012).
120. Yin X, Chen Y, Zhang L, Wang Y, Zabriskie TM. Enduracidin analogues with altered halogenation patterns produced by genetically engineered strains of Streptomyces fungicidicus. J. Nat. Prod. 73(4), 583-589 (2010).
121. Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34(3), 413-419 (1990).
122. Brötz H, Josten M, Wiedemann I, et al.: Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30(2), 317-327 (1998).
123. Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. Mol. Biosys. 2(1), 69-76 (2006).
124. Lo M-C, Men H, Branstrom A, et al.: A new mechanism of action proposed for ramoplanin. J. Am. Chem. Soc. 122(14), 3540-3541 (2000).
125. Helm JS, Chen L, Walker S. Rethinking ramoplanin: The role of substrate binding in inhibition of peptidoglycan biosynthesis. J. Am. Chem. Soc. 124(47), 13970-13971 (2002).
126. McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W. Chemistry and biology of the ramoplanin family of peptide antibiotics. Pept. Sci. 66(4), 261-284 (2002).
127. Wong MT, Kauffman CA, Standiford HC, et al.: Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin. Infect. Dis. 33(9), 1476-1482 (2001).
128. Pullman J, Prieto J, Leach TS. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: A Phase II study (Abstracts). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November 2004.
129. Fulco P, Wenzel RP. Ramoplanin: A topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti Infect. Ther. 4(6), 939-945 (2006).
130. Schmidt JW, Greenough A, Burns M, Luteran AE, McCafferty DG. Generation of ramoplanin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 310(2), 104-111 (2010).
131. Beatty PH, Jensen SE. Paenibacillus polymyxa produces fusaricidin-Type antifungal antibiotics active against Leptosphaeria maculans, the causative agent of blackleg disease of canola. Can. J. Microbiol. 48(2), 159-169 (2002).
132. Stawikowski M, Cudic P. A novel strategy for the solid-phase synthesis of cyclic lipodepsipeptides. Tetrahedron Lett. 47(48), 8587-8590 (2006).
133. Cochrane JR, McErlean CSP, Jolliffe KA. Total synthesis and assignment of the side chain stereochemistry of LI-F04a: An antimicrobial cyclic depsipeptide. Org. Lett. 12(15), 3394-3397 (2010).
134. Corchrane JR, Yoon DH, McErlean CSP, Jolliffe K. A macrolactonization approach of the antimicrobial cyclic depsipeptide LI-F04a and diastereomeric analogues. Beilstein J. Org. Chem. 8, 1344-1351 (2012).
135. Li J, Beatty PK, Shah S, Jensen SE. Use of PCR-Targeted mutagenesis to disrupt production of fusaricidin-Type antifungal antibiotics in Paenibacillus polymyxa. Appl. Environ. Microbiol. 73(11), 3480-3489 (2007).
136. Choi S-K, Park S-Y, Kim R, Lee C-H, Kim JF, Park S-H. Identification and functional analysis of the fusaricidin biosynthetic gene of Paenibacillus polymyxa E681. Biochem. Bioph. Res. Co. 365(1), 89-95 (2008).
137. Marty FM, Yeh WW, Wennersten CB, et al.: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44(2), 595-597 (2006).